Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15372562 | 1.00 | LMNA (0.31) | LMNAMCL1POLBMEN1KMT2A | |
| SCHEMBL21501463 | 1.00 | LMNA (0.31) | LMNAMCL1POLBMEN1KMT2A | |
| SCHEMBL12797870 | 0.96 | — | — | |
| SCHEMBL22618173 | 0.89 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL11514362 | 0.89 | LMNA (0.37) | LMNAMCL1POLBMEN1KMT2A | |
| SCHEMBL24506675 | 0.83 | CES2 (0.31) | LMNAMCL1POLBMEN1KMT2A | |
| SCHEMBL20801430 | 0.83 | LMNA (0.40) | LMNAMCL1POLBMEN1KMT2A | |
| SCHEMBL17168484 | 0.83 | CES2 (0.31) | LMNAMCL1POLBMEN1KMT2A | |
| SCHEMBL762258 | 0.83 | LMNA (0.40) | LMNAMCL1POLBMEN1KMT2A | |
| SCHEMBL27262127 | 0.83 | LMNA (0.40) | LMNAMCL1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021018018-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-02-04 | — | — | WO | disclosed |
| EP-3534936-B1 | TOLEROGENIC DNA VACCINE | NOVO NORDISK AS (DK) | 2020-10-21 | — | — | EP | disclosed |
| US-20140371148-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | ASTRAZENECA PHARMACEUTICALS LP | 2014-12-18 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| EP-2322538-B9 | Compounds for the diagnosis of diseases associated with VCAM expression | GUERBET SA (FR) | 2012-11-21 | — | — | EP | disclosed |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| EP-2322538-B1 | Compounds for the diagnosis of diseases associated with VCAM expression | GUERBET SA (FR) | 2012-05-23 | — | — | EP | disclosed |
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | LMNA 3156/4885MCL1 2249/4885POLB 884/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | LMNA 2657/4885MCL1 1199/4885POLB 3408/4885 |
| US-20120191039-A1 | CARRIER LINKED PRAMIPEXOLE PRODRUGS | PRAP1, LPXN, DNPEP | LMNA 1878/4885MCL1 4718/4885POLB 3711/4885 |
| US-20140371148-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | DNPEP, PEPD, VIP | LMNA 2488/4885MCL1 3911/4885POLB 3355/4885 |
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | DNPEP, PEPD, VIP | LMNA 2206/4885MCL1 3038/4885POLB 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.